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Autosomal Dominant Alzheimer’s Disease (ADAD), the rarest form of Alzheimer’s 
disease (AD), leads to early onset dementia and is due to a mutation within Amyloid 
Precursor Protein (APP), Presenilin-1 (PSEN-1), or Presenilin-2 (PSEN-2) genes. Each 
mutation alters the metabolism of β-amyloid (Aβ)—the protein considered to be a 
driving force in the physiopathogenic cascade of AD—and guarantees AD development. 
Like the more common, sporadic form of AD, abnormalities observed in ADAD are 
cerebral microbleeds (CMBs) and severe white matter hyperintensity (WMH), which 
are detected with imaging tools. The aim here is to evaluate these two features and their 
relationship with ADAD genotypes.
The Dominantly Inherited Alzheimer Network (DIAN) enrolls participants at risk 
for ADAD, and performs clinical, cognitive, imaging, and biochemical assessments. 
The symptom onset in ADAD is approximated by the afflicted parent’s age of disease 
onset, and is termed estimated years to onset (EYO). CMBs and WMH can be observed 
even before symptom onset, and are indications of vascular abnormalities. Studies have 
shown that AD individuals with severe WMH have more CMBs.
Among ADAD mutations, the expression of the imaging biomarkers is variable. The 
PSEN-1 mutation is the most common mutation and has exhibited severe AD pathology. 
Using the DIAN data, I will correlate the participants’ WMH volumes with CMBs counts, 
using factors such as EYO, cognitive impairment and the mutation type. I hypothesize 
that PSEN-1 carriers have more severe WMH and CMBs when compared to the other 
two mutations. I aim to further establish the trend outlined by previous studies. Further 
understanding ADAD pathology will increase our ability to devise therapies to control 
and combat AD as a whole.
